Latest Nabi Biopharmaceuticals Stories
ROCKVILLE, Md., Oct.
Nabi Biopharmaceuticals has announced that the National Institute of Allergy and Infectious Diseases, one of the National Institutes of Health, has entered into collaboration with Nabi to advance the company's PentaStaph vaccine candidate for the prevention and treatment of Staphylococcus aureus infections in the community and hospital settings.
ROCKVILLE, Md., Sept.
ROCKVILLE, Md., July 23, 2008 (PRIME NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today positive interim results from its Phase 2 NicVAX(r) (Nicotine Conjugate Vaccine) schedule optimization immunogenicity study to assess the antibody response and safety of a 400 microgram, six dose immunization schedule.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.